201 related articles for article (PubMed ID: 19533748)
1. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients.
Derhovanessian E; Adams V; Hähnel K; Groeger A; Pandha H; Ward S; Pawelec G
Int J Cancer; 2009 Sep; 125(6):1372-9. PubMed ID: 19533748
[TBL] [Abstract][Full Text] [Related]
2. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
[TBL] [Abstract][Full Text] [Related]
3. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Yokokawa J; Cereda V; Remondo C; Gulley JL; Arlen PM; Schlom J; Tsang KY
Clin Cancer Res; 2008 Feb; 14(4):1032-40. PubMed ID: 18281535
[TBL] [Abstract][Full Text] [Related]
4. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
[TBL] [Abstract][Full Text] [Related]
5. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
[TBL] [Abstract][Full Text] [Related]
6. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
7. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
9. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.
Bovenschen HJ; van de Kerkhof PC; van Erp PE; Woestenenk R; Joosten I; Koenen HJ
J Invest Dermatol; 2011 Sep; 131(9):1853-60. PubMed ID: 21654831
[TBL] [Abstract][Full Text] [Related]
10. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
11. High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma.
Chen B; Zhang D; Zhou J; Li Q; Zhou L; Li SM; Zhu L; Chou KY; Zhou L; Tao L; Lu LM
Oncol Rep; 2013 Sep; 30(3):1380-90. PubMed ID: 23835793
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Th17 cells and CD4⁺CD25⁺ regulatory T cells with clinical parameters in patients with systemic sclerosis.
Jiang N; Li M; Zeng X
Chin Med J (Engl); 2014; 127(20):3557-61. PubMed ID: 25316229
[TBL] [Abstract][Full Text] [Related]
13. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue.
Valdman A; Jaraj SJ; Compérat E; Charlotte F; Roupret M; Pisa P; Egevad L
APMIS; 2010 May; 118(5):360-5. PubMed ID: 20477811
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with allergic asthma.
Shi YH; Shi GC; Wan HY; Jiang LH; Ai XY; Zhu HX; Tang W; Ma JY; Jin XY; Zhang BY
Chin Med J (Engl); 2011 Jul; 124(13):1951-6. PubMed ID: 22088452
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+CD127- assessment as a surrogate phenotype for FOXP3+ regulatory T cells in HIV-1 infected viremic and aviremic subjects.
Saison J; Demaret J; Venet F; Chidiac C; Malcus C; Poitevin-Later F; Tardy JC; Ferry T; Monneret G
Cytometry B Clin Cytom; 2013; 84(1):50-4. PubMed ID: 23019018
[TBL] [Abstract][Full Text] [Related]
16. FOXP3-marked IL-17a-producing regulatory T cells are increased in patients with allergic rhinitis.
Cheng X; Lou W; Wang C; Zhang W; Han D; Zhang L
Acta Otolaryngol; 2012 Dec; 132(12):1311-7. PubMed ID: 22992221
[TBL] [Abstract][Full Text] [Related]
17. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
[TBL] [Abstract][Full Text] [Related]
18. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination.
Correll A; Tuettenberg A; Becker C; Jonuleit H
Exp Dermatol; 2010 Aug; 19(8):e213-21. PubMed ID: 20500773
[TBL] [Abstract][Full Text] [Related]
19. Cytokine production profile of CD4+ T cells from patients with active Churg-Strauss syndrome tends toward Th17.
Saito H; Tsurikisawa N; Tsuburai T; Oshikata C; Akiyama K
Int Arch Allergy Immunol; 2009; 149 Suppl 1():61-5. PubMed ID: 19494507
[TBL] [Abstract][Full Text] [Related]
20. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
